M&As, restructuring to sweep pharmaceutical industry

The government’s plan to cut prices for drugs covered by health insurance by an average of 17 percent will make it harder for companies to do business.

Analysts expect a large number of mergers and acquisitions (M&A) to take place among companies, and restructuring seems inevitable to offset worsening profitability.

However, research and development (R&D)-oriented pharmaceutical firms, su...